From Dealroom · · 50s
Isomorphic Labs Targets $40B Valuation
Isomorphic Labs, DeepMind's AI drug discovery spinout, aims for $40 billion valuation after May's $2.1 billion funding round.
In brief
Isomorphic Labs, DeepMind's AI drug discovery spinout, aims for $40 billion valuation after May's $2.1 billion funding round. Isomorphic Labs, a DeepMind spinout using AI for drug discovery, targets a $40 billion valuation following a $2.1 billion Series B round in May. Originally reported by Dealroom.
Isomorphic Labs
Isomorphic Labs, the Google DeepMind spinout applying AI to drug discovery, is in early talks to raise a Series C at a valuation of at least $40 billion.
Funding Round Details
The financing has not closed, and neither the round size nor the investors have been reported.
Market Context
A $40 billion valuation would rank among the largest in the sector, with AI in drug discovery estimated at $2.3 billion in 2025, growing to $13.8 billion by 2033.
At a glance
Isomorphic Labs, a DeepMind spinout using AI for drug discovery, targets a $40 billion valuation following a $2.1 billion Series B round in May.
